<DOC>
	<DOCNO>NCT00337818</DOCNO>
	<brief_summary>The study extend subject receive three dos vaccine Finland , Denmark Estonia determine long-term safety immunogenicity HPV-16/18 vaccine . Human Papilloma virus ( HPV ) viruses cause common infection skin genitals men woman . Several type HPV infection transmit sexual activity , woman , infect cervix ( part uterus womb ) . This infection often go away , go away ( call persistent infection ) , lead woman long period time cancer cervix . If woman infect HPV , unlikely get cervical cancer . This study evaluate consistency consecutive vaccine lot non-inferiority modify manufacturing process GlaxoSmithKline Biologicals HPV-16/18 vaccine vaccine safety , 12 month , young adolescent woman 10-25 year age study start .</brief_summary>
	<brief_title>Human Papillomavirus ( HPV ) Vaccine Consistency Non-inferiority Trial Young Adult Women</brief_title>
	<detailed_description>Approximately 750 study subject receive different lot HPV vaccine administer intramuscularly accord 0-1-6 month schedule . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</detailed_description>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A female enrol HPV012 ( NCT00337818 ) study Denmark , Estonia Finland , receive three dos vaccine complete Visit 4 ( Month 7 ) . Written inform consent obtain subject prior enrolment ( subject legal age consent , write informed consent must obtain parent legally acceptable representative ( LAR ) , addition , subject must sign personally date write informed assent ) . Exclusion criterion Use investigational nonregistered product ( drug vaccine ) plan use study period . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product ( pharmaceutical product device ) . Chronic administration immunosuppressant immunemodifying drug occur less three month prior blood sampling . Administration immunoglobulins and/or blood product within three month precede blood sampling .</criteria>
	<gender>Female</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Non-inferiority</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>HPV Vaccine Consistency</keyword>
</DOC>